CoChat

Geographical similarity and differences in the burden and genetic predisposition of NAFLD

Yip, Terry Cheuk‐Fung, Vilar‐Gomez, Eduardo, Petta, Salvatore, Yilmaz, Yusuf, Wong, Grace Lai‐Hung, Adams, Leon A., de Lédinghen, Victor, Sookoian, Silvia, Wong, Vincent Wai‐Sun · 2023 · Hepatology
Cited by 123

The DOI matches its Crossref record; 43 of the 43 references it cites were found in a registry or an index.

Abstract

NAFLD has become a major public health problem for more than 2 decades with a growing prevalence in parallel with the epidemic of obesity and type 2 diabetes (T2D). The disease burden of NAFLD differs across geographical regions and ethnicities. Variations in prevalence of metabolic diseases, extent of urban–rural divide, dietary habits, lifestyles, and the prevalence of NAFLD risk and protective alleles can contribute to such differences. The rise in NAFLD has led to a remarkable increase in the number of cases of cirrhosis, hepatocellular carcinoma, hepatic decompensation, and liver‐related mortality related to NAFLD. Moreover, NAFLD is associated with multiple extrahepatic manifestations. Most of them are risk factors for the progression of liver fibrosis and thus worsen the prognosis of NAFLD. All these comorbidities and complications affect the quality of life in subjects with NAFLD. Given the huge and growing size of the population with NAFLD, it is expected that patients, healthcare systems, and the economy will suffer from the ongoing burden related to NAFLD. In this review, we examine the disease burden of NAFLD across geographical areas and ethnicities, together with the distribution of some well‐known genetic variants for NAFLD. We also describe some special populations including patients with T2D, lean patients, the pediatric population, and patients with concomitant liver diseases. We discuss extrahepatic outcomes, patient‐reported outcomes, and economic burden related to NAFLD.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1002/hep.32774

Cites

43 of 43 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Research works printed but not linked: 175

  1. 2018, Modeling NAFLD disease burden in China, France, Germany, Italy, Japan, Spain, United Kingdom, and United States for the period 2016‐2030, J Hepatol, 69, 896, 10.1016/j.jhep.2018.05.036 · DOI · Paper page
  2. 2020, Modelling NAFLD disease burden in four Asian regions‐2019–2030, Aliment Pharmacol Ther, 51, 801, 10.1111/apt.15673 · DOI · Paper page
  3. 2021, Nonalcoholic steatohepatitis is the most rapidly increasing indication for liver transplantation in the United States, Clin Gastroenterol Hepatol, 19, 580, 10.1016/j.cgh.2020.05.064 · DOI · Paper page
  4. 2019, Nonalcoholic steatohepatitis is the fastest growing cause of hepatocellular carcinoma in liver transplant candidates, Clin Gastroenterol Hepatol, 17, 748, 10.1016/j.cgh.2018.05.057 · DOI · Paper page
  5. 2021, Clinical and patient‐reported outcomes from patients with nonalcoholic fatty liver disease across the world: data from the Global Non‐Alcoholic Steatohepatitis (NASH)/Non‐Alcoholic Fatty Liver Disease (NAFLD) Registry, Clin Gastroenterol Hepatol
  6. 2016, The economic and clinical burden of nonalcoholic fatty liver disease in the United States and Europe, Hepatology, 64, 1577, 10.1002/hep.28785 · DOI · Paper page
  7. 2018, Nonalcoholic fatty liver disease and risk of incident type 2 diabetes: a meta‐analysis, Diabetes Care, 41, 372, 10.2337/dc17-1902 · DOI · Paper page
  8. 2018, Fibrosis severity as a determinant of cause‐specific mortality in patients with advanced nonalcoholic fatty liver disease: a multi‐national cohort study, Gastroenterology, 155, 443, 10.1053/j.gastro.2018.04.034 · DOI · Paper page
  9. 2021, On the proposed definition of metabolic‐associated fatty liver disease, Clin Gastroenterol Hepatol, 19, 865, 10.1016/j.cgh.2021.01.017 · DOI
  10. 2022, Nonalcoholic fatty liver disease: current global burden, Semin Liver Dis, 42, 401, 10.1055/a-1862-9088 · DOI
  11. 2014, Nonalcoholic steatohepatitis is the most rapidly growing indication for liver transplantation in patients with hepatocellular carcinoma in the U.S, Hepatology, 59, 2188, 10.1002/hep.26986 · DOI · Paper page
  12. 2013, Prevalence of nonalcoholic fatty liver disease in the United States: the Third National Health and Nutrition Examination Survey, 1988–1994, Am J Epidemiol, 178, 38, 10.1093/aje/kws448 · DOI · Paper page
  13. 2011, Prevalence of nonalcoholic fatty liver disease and nonalcoholic steatohepatitis among a largely middle‐aged population utilizing ultrasound and liver biopsy: a prospective study, Gastroenterology, 140, 124, 10.1053/j.gastro.2010.09.038 · DOI · Paper page
  14. 2020, Prevalence, characteristics and mortality outcomes of obese, nonobese and lean NAFLD in the United States, 1999–2016, J Intern Med, 288, 139, 10.1111/joim.13069 · DOI · Paper page
  15. 2019, Race/ethnicity‐based temporal changes in prevalence of NAFLD‐related advanced fibrosis in the United States, 2005–2016, Hepatol Int, 13, 205, 10.1007/s12072-018-09926-z · DOI
  16. 2021, Prevalence and factors associated with NAFLD detected by vibration controlled transient elastography among US adults: results from NHANES 2017–2018, PLoS One, 16
  17. 2021, Prevalence of high‐risk nonalcoholic steatohepatitis (NASH) in the United States: results from NHANES 2017‐2018, Clin Gastroenterol Hepatol
  18. 2016, Trends in the burden of nonalcoholic fatty liver disease in a United States cohort of veterans, Clin Gastroenterol Hepatol, 14, 301, 10.1016/j.cgh.2015.08.010 · DOI · Paper page
  19. 2017, Diagnostic accuracy of noninvasive fibrosis scores in a population of individuals with a low prevalence of fibrosis, Clin Gastroenterol Hepatol, 15, 1453, 10.1016/j.cgh.2017.02.031 · DOI
  20. 2021, Impact of the new definition of metabolic associated fatty liver disease on the epidemiology of the disease, Clin Gastroenterol Hepatol, 19, 2161, 10.1016/j.cgh.2020.10.046 · DOI · Paper page
  21. 2021, Non‐alcoholic fatty liver disease in children and young adults is associated with increased long‐term mortality, J Hepatol, 75, 1034, 10.1016/j.jhep.2021.06.034 · DOI · Paper page
  22. 2010, Decreased survival of subjects with elevated liver function tests during a 28‐year follow‐up, Hepatology, 51, 595, 10.1002/hep.23314 · DOI · Paper page
  23. 2016, Nonalcoholic fatty liver disease in Latinos, Clin Gastroenterol Hepatol, 14, 5, 10.1016/j.cgh.2015.05.001 · DOI
  24. 2019, Nonalcoholic fatty liver disease risk factors in Latin American populations: current scenario and perspectives, Clin Liver Dis (Hoboken), 13, 39, 10.1002/cld.759 · DOI · Paper page
  25. 2007, Non‐alcoholic fatty liver disease and metabolic syndrome in Brazilian middle‐aged and older adults, Sao Paulo Med J, 125, 333, 10.1590/S1516-31802007000600006 · DOI · Paper page
  26. 2003, Prevalence of liver steatosis in abdominal ultrasound, GED, 22, 235
  27. 2011, Nonalcoholic fatty liver disease is associated with insulin resistance in a young Hispanic population, Prev Med, 52, 174, 10.1016/j.ypmed.2010.11.021 · DOI · Paper page
  28. 2009, Non‐alcoholic fatty liver disease and its association with obesity, insulin resistance and increased serum levels of C‐reactive protein in Hispanics, Liver Int, 29, 82, 10.1111/j.1478-3231.2008.01823.x · DOI · Paper page
  29. 2022, Non‐alcoholic fatty liver disease prevalence in Latin America: a systematic review and meta‐analysis, Ann Hepatol
  30. 2006, Prevalence of NAFLD and metabolic syndrome in asymtomatics subjects, Rev Gastroenterol Mex, 71, 453
  31. 2006, Frequency of NAFLD in a group of patients with metabolic syndrome in Veracruz, Mexico, Rev Gastroenterol Mex, 71, 446
  32. 2021, NAFLD: challenges and opportunities to address the public health problem in Latin America, Ann Hepatol, 24
  33. 2022, The establishment of public health policies and the burden of non‐alcoholic fatty liver disease in the Americas, Lancet Gastroenterol Hepatol, 7, 552, 10.1016/S2468-1253(22)00008-5 · DOI
  34. 2011, Nonalcoholic fatty liver disease in Brazil. Clinical and histological profile, Ann Hepatol, 10, 33, 10.1016/S1665-2681(19)31584-4 · DOI
  35. 2005, Predictors of nonalcoholic steatohepatitis (NASH) in obese patients undergoing gastric bypass, Obes Surg, 15, 1148, 10.1381/0960892055002347 · DOI · Paper page
  36. 2018, A rare nonsense mutation in the glucokinase regulator gene is associated with a rapidly progressive clinical form of nonalcoholic steatohepatitis, Hepatol Commun, 2, 1030, 10.1002/hep4.1235 · DOI
  37. 2017, The expression of PNPLA3 polymorphism could be the key for severe liver disease in NAFLD in Hispanic population, Ann Hepatol, 16, 909, 10.5604/01.3001.0010.5282 · DOI · Paper page
  38. 2019, Diabetes in Latin America: prevalence, complications, and socio‐economic impact, Int J Diabetes Clin Res, 6
  39. 2020, A Latin American survey on demographic aspects of hospitalized, decompensated cirrhotic patients and the resources for their management, Ann Hepatol, 19, 396, 10.1016/j.aohep.2020.03.007 · DOI
  40. 2018, Fatty liver disease, an emerging etiology of hepatocellular carcinoma in Argentina, World J Hepatol, 10, 41, 10.4254/wjh.v10.i1.41 · DOI
  41. 2022, The burden of NAFLD in type 2 diabetic subjects from the general population: a Nationwide population‐based follow‐up study (NASHCO), Liver Int, 42, 595, 10.1111/liv.15171 · DOI
  42. 2012, Heritability of non‐alcoholic fatty liver disease and association with abnormal vascular parameters: a twin study, Liver Int, 32, 1287, 10.1111/j.1478-3231.2012.02823.x · DOI · Paper page
  43. 2018, Prevalence and severity of nonalcoholic fatty liver disease by transient elastography: genetic and metabolic risk factors in a general population, Liver Int, 38, 2060, 10.1111/liv.13743 · DOI · Paper page
  44. 2015, Subclinical and clinical hypothyroidism and non‐alcoholic fatty liver disease: a cross‐sectional study of a random population sample aged 18 to 65 years, BMC Endocr Disord, 15
  45. 2018, High prevalence of liver fibrosis among European adults with unknown liver disease: a population‐based study, Clin Gastroenterol Hepatol, 16, 1138, 10.1016/j.cgh.2017.12.048 · DOI · Paper page
  46. 2020, Hospitalization costs and risk of mortality in adults with nonalcoholic steatohepatitis: analysis of a French national hospital database, eClinicalMedicine, 25
  47. 2020, Disease severity predicts higher healthcare costs among hospitalized nonalcoholic fatty liver disease/nonalcoholic steatohepatitis (NAFLD/NASH) patients in Spain, Medicine (Baltimore), 99
  48. 2020, Healthcare resource utilization and costs of nonalcoholic steatohepatitis patients with advanced liver disease in Italy, Nutr Metab Cardiovasc Dis, 30, 1014, 10.1016/j.numecd.2020.02.016 · DOI
  49. 2007, Incidence and natural course of fatty liver in the general population: the Dionysos study, Hepatology, 46, 1387, 10.1002/hep.21827 · DOI · Paper page
  50. 2010, Prevalence of liver fibrosis and risk factors in a general population using non‐invasive biomarkers (FibroTest), BMC Gastroenterol, 10
  51. 2011, Transient elastography as a screening tool for liver fibrosis and cirrhosis in a community‐based population aged over 45 years, Gut, 60, 977, 10.1136/gut.2010.221382 · DOI · Paper page
  52. 2016, Presence of diabetes mellitus and steatosis is associated with liver stiffness in a general population: the Rotterdam study, Hepatology, 63, 138, 10.1002/hep.27981 · DOI · Paper page
  53. 2020, Prevalence of steatosis and fibrosis in young adults in the UK: a population‐based study, Lancet Gastroenterol Hepatol, 5, 295, 10.1016/S2468-1253(19)30419-4 · DOI · Paper page
  54. 2021, NR1H4 rs35724 G>C variant modulates liver damage in nonalcoholic fatty liver disease, Liver Int, 41, 2712, 10.1111/liv.15016 · DOI
  55. 2021, Definite and indeterminate nonalcoholic steatohepatitis share similar clinical features and prognosis: a longitudinal study of 1893 biopsy‐proven nonalcoholic fatty liver disease subjects, Liver Int, 41, 2076, 10.1111/liv.14898 · DOI
  56. 2021, NAFLD and MAFLD as emerging causes of HCC: a populational study, JHEP Rep, 3
  57. 2021, Epidemiological trends and trajectories of MAFLD‐associated hepatocellular carcinoma 2002‐2033: the ITA.LI.CA database, Gut
  58. 2022, Trends and the course of liver cirrhosis and its complications in Germany: nationwide population‐based study (2005 to 2018), Lancet Reg Health Eur, 12
  59. 2020, Changes in the global burden of chronic liver diseases from 2012 to 2017: the growing impact of NAFLD, Hepatology, 72, 1605, 10.1002/hep.31173 · DOI · Paper page
  60. 2019, Prevalence, incidence, and outcome of non‐alcoholic fatty liver disease in Asia, 1999‐2019: a systematic review and meta‐analysis, Lancet Gastroenterol Hepatol, 4, 389, 10.1016/S2468-1253(19)30039-1 · DOI · Paper page
  61. 2020, Prevalence trends in non‐alcoholic fatty liver disease at the global, regional and national levels, 1990–2017: a population‐based observational study, BMJ Open, 10
  62. 2013, Prevalence and risk factors of non‐alcoholic fatty liver disease in a multiracial suburban Asian population in Malaysia, Hepatol Int, 7, 548, 10.1007/s12072-012-9359-2 · DOI
  63. 2019, Association between non‐alcoholic fatty liver disease evaluated by transient elastography with extracranial carotid atherosclerosis in a multiethnic Asian community, JGH Open, 3, 117, 10.1002/jgh3.12114 · DOI
  64. 2016, Perceptions of non‐alcoholic fatty liver disease—an Asian community‐based study, Gastroenterol Rep (Oxf), 4, 131, 10.1093/gastro/gov047 · DOI · Paper page
  65. 2015, Development of non‐alcoholic fatty liver disease scoring system among adult medical check‐up patients: a large cross‐sectional and prospective validation study, Diabetes Metab Syndr Obes, 8, 213
  66. 2019, Unexpected rapid increase in the burden of NAFLD in China from 2008 to 2018: a systematic review and meta‐analysis, Hepatology, 70, 1119, 10.1002/hep.30702 · DOI · Paper page
  67. 2020, Epidemiological features of NAFLD from 1999 to 2018 in China, Hepatology, 71, 1851, 10.1002/hep.31150 · DOI · Paper page
  68. 2012, Prevalence of non‐alcoholic fatty liver disease and advanced fibrosis in Hong Kong Chinese: a population study using proton‐magnetic resonance spectroscopy and transient elastography, Gut, 61, 409, 10.1136/gutjnl-2011-300342 · DOI · Paper page
  69. 2021, The epidemiology of NAFLD and lean NAFLD in Japan: a meta‐analysis with individual and forecasting analysis, 1995–2040, Hepatol Int, 15, 366, 10.1007/s12072-021-10143-4 · DOI
  70. 2016, Nonalcoholic fatty liver disease in South Asia, Euroasian J Hepatogastroenterol, 6, 154
  71. 2021, Systematic review on the prevalence of nonalcoholic fatty liver disease in South Korea, Clin Res Hepatol Gastroenterol, 45
  72. 2022, Clinicopathological profile and outcome of a large cohort of patients with nonalcoholic fatty liver disease from South Asia: interim results of the Indian Consortium on Nonalcoholic Fatty Liver Disease, Metab Syndr Relat Disord, 20, 166, 10.1089/met.2021.0104 · DOI
  73. 2018, Asia‐Pacific Working Party on Non‐alcoholic Fatty Liver Disease guidelines 2017‐Part 1: definition, risk factors and assessment, J Gastroenterol Hepatol, 33, 70, 10.1111/jgh.13857 · DOI · Paper page
  74. 2021, NASH/liver fibrosis prevalence and incidence of nonliver comorbidities among people with NAFLD and incidence of NAFLD by metabolic comorbidities: lessons from South Korea, Dig Dis, 39, 634, 10.1159/000514953 · DOI
  75. 2022, Influence of nonalcoholic fatty liver disease with increased liver enzyme levels on the risk of cirrhosis and hepatocellular carcinoma, Clin Gastroenterol Hepatol
  76. 2021, The incidence trends of liver cirrhosis caused by nonalcoholic steatohepatitis via the GBD study 2017, Sci Rep, 11
  77. 2017, Association between non‐alcoholic fatty liver disease and cancer incidence rate, J Hepatol, 68, 140
  78. 2017, The occurrence of hepatocellular carcinoma in different risk stratifications of clinically noncirrhotic nonalcoholic fatty liver disease, Int J Cancer, 141, 1307, 10.1002/ijc.30784 · DOI · Paper page
  79. 2022, Asian perspective on NAFLD‐associated HCC, J Hepatol, 76, 726, 10.1016/j.jhep.2021.09.024 · DOI · Paper page
  80. 2011, Relative etiological role of prior hepatitis B virus infection and nonalcoholic fatty liver disease in the development of non‐B non‐C hepatocellular carcinoma in a hepatitis B‐endemic area, Digestion, 84, 17
  81. 2019, A nationwide survey on non‐B, non‐C hepatocellular carcinoma in Japan: 2011–2015 update, J Gastroenterol, 54, 367, 10.1007/s00535-018-1532-5 · DOI · Paper page
  82. 2019, Comparison of hepatocellular carcinoma in patients with cryptogenic versus hepatitis B etiology: a study of 1079 cases over 3 decades, Dig Dis Sci, 64, 585, 10.1007/s10620-018-5331-x · DOI
  83. 2020, Positive hepatitis B core antibody is associated with cirrhosis and hepatocellular carcinoma in nonalcoholic fatty liver disease, Am J Gastroenterol, 115, 867, 10.14309/ajg.0000000000000588 · DOI · Paper page
  84. 2018, Nonalcoholic fatty liver disease‐associated hepatocellular carcinoma in a hepatitis B virus‐endemic area, Eur J Gastroenterol Hepatol, 30, 1090, 10.1097/MEG.0000000000001174 · DOI
  85. 2021, Burden of non‐alcoholic fatty liver disease in Asia, the Middle East and North Africa: data from Global Burden of Disease 2009–2019, J Hepatol, 75, 795, 10.1016/j.jhep.2021.05.022 · DOI · Paper page
  86. 2018, Nonalcoholic fatty liver disease burden—Saudi Arabia and United Arab Emirates, 2017–2030, Saudi J Gastroenterol, 24, 211, 10.4103/sjg.SJG_122_18 · DOI · Paper page
  87. 2006, Prevalence of primary non‐alcoholic fatty liver disease in a population‐based study and its association with biochemical and anthropometric measures, Liver Int, 26, 856, 10.1111/j.1478-3231.2006.01311.x · DOI · Paper page
  88. 2012, Nonalcoholic fatty liver disease of two ethnic groups in Kuwait: comparison of prevalence and risk factors, Med Princ Pract, 21, 56, 10.1159/000331591 · DOI
  89. 2021, Prevalence of and risk factors for non‐alcoholic fatty liver disease (NAFLD) and fibrosis among young adults in Egypt, BMJ Open Gastroenterol, 8
  90. 2021, The changing prevalence of non‐alcoholic fatty liver disease (NAFLD) in Turkey in the last decade, Turk J Gastroenterol, 32, 302, 10.5152/tjg.2021.20062 · DOI
  91. 2016, The prevalence of non‐alcoholic fatty liver disease in healthy young persons, North Clin Istanb, 3, 111
  92. 2016, Prevalence of hepatic steatosis in apparently healthy medical students: a transient elastography study on the basis of a controlled attenuation parameter, Eur J Gastroenterol Hepatol, 28, 1264, 10.1097/MEG.0000000000000681 · DOI
  93. 2012, Epidemiological, clinical, and biochemical characteristics of Saudi patients with nonalcoholic fatty liver disease: a hospital‐based study, Ann Saudi Med, 32, 288, 10.5144/0256-4947.2012.288 · DOI · Paper page
  94. 2013, Low vitamin D levels are associated with increased risk for fatty liver disease among non‐obese adults, Clin Med (Lond), 13, 576
  95. 2020, Spectrum of liver diseases in patients referred for Fibroscan: a single center experience in the Middle East, Ann Med Surg (Lond), 57, 166, 10.1016/j.amsu.2020.07.040 · DOI
  96. 2021, The prevalence of metabolic‐associated fatty liver disease in the Turkish population: a multicenter study, Hepatol Forum, 2, 37
  97. 2021, Clinical and metabolic characteristics of non‐alcoholic fatty liver disease patients in Saudi Arabia: data from the Systematic Observatory Liver Disease (SOLID) Registry, Diabetes Metab Syndr Obes, 14, 1167, 10.2147/DMSO.S300051 · DOI
  98. 2019, Screening for hepatic fibrosis and steatosis in Turkish patients with type 2 diabetes mellitus: a transient elastography study, Turk J Gastroenterol, 30, 266, 10.5152/tjg.2018.18559 · DOI
  99. 2019, Growing burden of nonalcoholic fatty liver disease in Turkey: a single‐center experience, Turk J Gastroenterol, 30, 892, 10.5152/tjg.2019.19072 · DOI
  100. 2021, Natural history of cirrhosis: changing trends in etiology over the years, Dig Dis, 39, 358, 10.1159/000512746 · DOI
  101. 2021, Epidemiology, risk factors, social determinants of health, and current management for non‐alcoholic fatty liver disease in sub‐Saharan Africa, Lancet Gastroenterol Hepatol, 6, 1036, 10.1016/S2468-1253(21)00275-2 · DOI
  102. 2020, Prevalence of metabolic syndrome and nonalcoholic fatty liver disease among premenopausal and postmenopausal women in Ho Municipality: a cross‐sectional study, Biomed Res Int, 2020
  103. 2010, Non‐alcoholic fatty liver disease (NAFLD) in the Western Cape: a descriptive analysis, S Afr Med J, 100, 168, 10.7196/SAMJ.1422 · DOI · Paper page
  104. 2021, Current epidemiology in hepatocellular carcinoma, Expert Rev Gastroenterol Hepatol, 15, 1295, 10.1080/17474124.2021.1991792 · DOI · Paper page
  105. 2020, Epidemiology of liver cancer in Africa: current and future trends, Semin Liver Dis, 40, 111, 10.1055/s-0039-3399566 · DOI
  106. 2021, Prevalence of non‐alcoholic fatty liver disease in regional Victoria: a prospective population‐based study, Med J Aust, 215, 77, 10.5694/mja2.51096 · DOI
  107. 2022, A problem of proportions: estimates of metabolic associated fatty liver disease and liver fibrosis in Australian adults in the nationwide 2012 AusDiab Study, Sci Rep, 12
  108. 2011, Gender‐specific differences in adipose distribution and adipocytokines influence adolescent nonalcoholic fatty liver disease, Hepatology, 53, 800, 10.1002/hep.24097 · DOI · Paper page
  109. 2022, Alcohol consumption and cardiovascular outcomes in patients with nonalcoholic fatty liver disease: a population‐based cohort study, Hepatol Commun, 6, 526, 10.1002/hep4.1828 · DOI
  110. 2015, Noncommunicable diseases and risk factors in adult populations of several Pacific Islands: results from the WHO STEPwise approach to surveillance, Aust N Z J Public Health, 39, 336, 10.1111/1753-6405.12398 · DOI
  111. 2021, Increasing prevalence of NAFLD/NASH among children, adolescents and young adults from 1990 to 2017: a population‐based observational study, BMJ Open, 11
  112. 2020, Long‐term liver‐related outcomes of patients with chronic liver diseases in Australia, Clin Gastroenterol Hepatol, 18, 496, 10.1016/j.cgh.2019.07.013 · DOI
  113. 2020, Nonalcoholic fatty liver disease: interface between primary care and hepatology clinics, Hepatol Commun, 4, 518, 10.1002/hep4.1486 · DOI
  114. 2018, Non‐alcoholic fatty liver disease patients attending two metropolitan hospitals in Melbourne, Australia: high risk status and low prevalence, Intern Med J, 48, 1369, 10.1111/imj.13973 · DOI
  115. 2022, Predicting liver‐related outcomes in people with nonalcoholic fatty liver disease: the prognostic value of noninvasive fibrosis tests, Hepatol Commun, 6, 728, 10.1002/hep4.1852 · DOI
  116. 2018, Diabetes impacts prediction of cirrhosis and prognosis by non‐invasive fibrosis models in non‐alcoholic fatty liver disease, Liver Int, 38, 1793, 10.1111/liv.13739 · DOI · Paper page
  117. 2019, Increasing incidence of nonalcoholic steatohepatitis as an indication for liver transplantation in Australia and New Zealand, Liver Transpl, 25, 25, 10.1002/lt.25361 · DOI · Paper page
  118. 2018, Rate of nonsurveillance and advanced hepatocellular carcinoma at diagnosis in chronic liver disease, J Clin Gastroenterol, 52, 551, 10.1097/MCG.0000000000000916 · DOI
  119. 2021, Hepatocellular carcinoma amongst Aboriginal and Torres Strait Islander peoples of Australia, eClinicalMedicine, 36
  120. 2020, Nonalcoholic fatty liver disease burden: Australia, 2019–2030, J Gastroenterol Hepatol, 35, 1628, 10.1111/jgh.15009 · DOI · Paper page
  121. 2019, Genetics of nonalcoholic fatty liver disease: from pathogenesis to therapeutics, Semin Liver Dis, 39, 124, 10.1055/s-0039-1679920 · DOI · Paper page
  122. 2020, Genetic pathways in nonalcoholic fatty liver disease: insights from systems biology, Hepatology, 72, 330, 10.1002/hep.31229 · DOI · Paper page
  123. 2011, Meta‐analysis of the influence of I148M variant of patatin‐like phospholipase domain containing 3 gene (PNPLA3) on the susceptibility and histological severity of nonalcoholic fatty liver disease, Hepatology, 53, 1883, 10.1002/hep.24283 · DOI · Paper page
  124. 2020, Genome‐wide association study of non‐alcoholic fatty liver and steatohepatitis in a histologically characterised cohort, J Hepatol, 73, 505, 10.1016/j.jhep.2020.04.003 · DOI · Paper page
  125. 2019, 17‐beta hydroxysteroid dehydrogenase 13 is a hepatic retinol dehydrogenase associated with histological features of nonalcoholic fatty liver disease, Hepatology, 69, 1504, 10.1002/hep.30350 · DOI · Paper page
  126. 2019, Splice variant rs72613567 prevents worst histologic outcomes in patients with nonalcoholic fatty liver disease, J Lipid Res, 60, 176, 10.1194/jlr.P089953 · DOI · Paper page
  127. 2021, Loss‐of‐function HSD17B13 variants, non‐alcoholic steatohepatitis and adverse liver outcomes: results from a multi‐ethnic Asian cohort, Clin Mol Hepatol, 27, 486, 10.3350/cmh.2020.0162 · DOI
  128. 2013, Characterization of European ancestry nonalcoholic fatty liver disease‐associated variants in individuals of African and Hispanic descent, Hepatology, 58, 966, 10.1002/hep.26440 · DOI · Paper page
  129. 2016, Screening diabetic patients for non‐alcoholic fatty liver disease with controlled attenuation parameter and liver stiffness measurements: a prospective cohort study, Gut, 65, 1359, 10.1136/gutjnl-2015-309265 · DOI · Paper page
  130. 2020, Serial transient elastography examinations to monitor patients with type 2 diabetes: a prospective cohort study, Hepatology, 72, 1230, 10.1002/hep.31142 · DOI · Paper page
  131. 2021, ABIDE: an accurate predictive model of liver decompensation in patients with nonalcoholic fatty liver‐related cirrhosis, Hepatology, 73, 2238, 10.1002/hep.31576 · DOI
  132. 2017, New trends on obesity and NAFLD in Asia, J Hepatol, 67, 862, 10.1016/j.jhep.2017.06.003 · DOI · Paper page
  133. 2018, Evaluating feasibility and accuracy of non‐invasive tests for nonalcoholic fatty liver disease in severe and morbid obesity, Int J Obes (Lond), 42, 1900, 10.1038/s41366-018-0007-3 · DOI
  134. 2017, Systematic review of bariatric surgery liver biopsies clarifies the natural history of liver disease in patients with severe obesity, Gut, 66, 1688, 10.1136/gutjnl-2016-312238 · DOI · Paper page
  135. 2018, Clinical features and treatment of nonalcoholic fatty liver disease across the Asia Pacific region‐the GO ASIA initiative, Aliment Pharmacol Ther, 47, 816, 10.1111/apt.14506 · DOI
  136. 2021, A prospective 5‐year study on the use of transient elastography to monitor the improvement of non‐alcoholic fatty liver disease following bariatric surgery, Sci Rep, 11
  137. 2022, Association of genetic variations with NAFLD in lean individuals, Liver Int, 42, 149, 10.1111/liv.15078 · DOI
  138. 2021, Recent epidemiology of nonalcoholic fatty liver disease, Gut Liver, 15, 206, 10.5009/gnl20127 · DOI · Paper page
  139. 2015, Prevalence and severity of nonalcoholic fatty liver disease in non‐obese patients: a population study using proton‐magnetic resonance spectroscopy, Am J Gastroenterol, 110, 1306, 10.1038/ajg.2015.235 · DOI · Paper page
  140. 2022, Non‐obese non‐alcoholic fatty liver disease (NAFLD) in Asia: an international registry study, Metabolism, 126
  141. 2018, Nonalcoholic fatty liver disease in children, Semin Liver Dis, 38, 1, 10.1055/s-0038-1627456 · DOI · Paper page
  142. 2021, Estimating global prevalence of metabolic dysfunction‐associated fatty liver disease in overweight or obese children and adolescents: systematic review and meta‐analysis, Int J Public Health, 66
  143. 2006, Prevalence of fatty liver in children and adolescents, Pediatrics, 118, 1388, 10.1542/peds.2006-1212 · DOI · Paper page
  144. 2021, Prevalence of liver steatosis and fibrosis detected by transient elastography in adolescents in the 2017–2018 National Health and Nutrition Examination Survey, Clin Gastroenterol Hepatol, 19, 384, 10.1016/j.cgh.2020.06.048 · DOI
  145. 2009, The natural history of non‐alcoholic fatty liver disease in children: a follow‐up study for up to 20 years, Gut, 58, 1538, 10.1136/gut.2008.171280 · DOI · Paper page
  146. 2002, Hepatitis C virus genotype 3 is cytopathic to hepatocytes: reversal of hepatic steatosis after sustained therapeutic response, Hepatology, 36, 1266, 10.1053/jhep.2002.36370 · DOI · Paper page
  147. 2018, Wilson disease, Nat Rev Dis Primers, 4
  148. 2006, Steatosis in chronic hepatitis C: why does it really matter?, Gut, 55, 123, 10.1136/gut.2005.069757 · DOI · Paper page
  149. 2021, Concurrence and impact of hepatic steatosis on chronic hepatitis B patients: a systematic review and meta‐analysis, Ann Transl Med, 9
  150. 2012, Hepatitis B virus infection and fatty liver in the general population, J Hepatol, 56, 533, 10.1016/j.jhep.2011.09.013 · DOI · Paper page
  151. 2007, Hepatic steatosis is associated with increased frequency of hepatocellular carcinoma in patients with hepatitis C‐related cirrhosis, Cancer, 109, 2490, 10.1002/cncr.22701 · DOI · Paper page
  152. 2017, Concurrent fatty liver increases risk of hepatocellular carcinoma among patients with chronic hepatitis B, J Gastroenterol Hepatol, 32, 667, 10.1111/jgh.13536 · DOI · Paper page
  153. 2020, Combined effects of alcohol and metabolic disorders in patients with chronic liver disease, Clin Gastroenterol Hepatol, 18, 995, 10.1016/j.cgh.2019.06.036 · DOI · Paper page
  154. 2006, Cofactors associated with liver disease mortality in an HBsAg‐positive Mediterranean cohort: 20 years of follow‐up, Int J Cancer, 119, 687, 10.1002/ijc.21882 · DOI
  155. 2017, Sarcopenia is associated with severe liver fibrosis in patients with non‐alcoholic fatty liver disease, Aliment Pharmacol Ther, 45, 510, 10.1111/apt.13889 · DOI · Paper page
  156. 2022, Risk of non‐alcoholic fatty liver disease in patients with chronic plaque psoriasis: an updated systematic review and meta‐analysis of observational studies, J Endocrinol Invest, 45, 1277, 10.1007/s40618-022-01755-0 · DOI
  157. 2021, Testosterone is associated with nonalcoholic steatohepatitis and fibrosis in premenopausal women with NAFLD, Clin Gastroenterol Hepatol, 19, 1267, 10.1016/j.cgh.2020.09.045 · DOI · Paper page
  158. 2020, Non‐alcoholic fatty liver disease in pregnancy is associated with adverse maternal and perinatal outcomes, J Hepatol, 73, 516, 10.1016/j.jhep.2020.03.049 · DOI · Paper page
  159. 2021, Non‐alcoholic fatty liver disease (NAFLD) in patients with psoriasis: a review of the hepatic effects of systemic therapies, Psoriasis (Auckl), 11, 151
  160. 2019, Depression is associated with non‐alcoholic fatty liver disease among adults in the United States, Aliment Pharmacol Ther, 50, 590, 10.1111/apt.15395 · DOI · Paper page
  161. 2021, Association of hepatic steatosis with major adverse cardiovascular events, independent of coronary artery disease, Clin Gastroenterol Hepatol, 19, 1480, 10.1016/j.cgh.2020.07.030 · DOI · Paper page
  162. 2021, Review article: non‐alcoholic fatty liver disease and cardiovascular diseases: associations and treatment considerations, Aliment Pharmacol Ther, 54, 1013, 10.1111/apt.16575 · DOI
  163. 2020, Nonalcoholic fatty liver disease and fibrosis associated with increased risk of cardiovascular events in a prospective study, Clin Gastroenterol Hepatol, 18, 2324, 10.1016/j.cgh.2019.12.026 · DOI · Paper page
  164. 2019, PROs of patient‐reported outcomes for nonalcoholic fatty liver disease and effects on treatment for nonalcoholic steatohepatitis, Clin Gastroenterol Hepatol, 17, 1950, 10.1016/j.cgh.2019.04.018 · DOI
  165. 2007, Health‐related quality of life in patients with non‐alcoholic fatty liver disease, Aliment Pharmacol Ther, 26, 815, 10.1111/j.1365-2036.2007.03426.x · DOI · Paper page
  166. 2009, Quality of life in adults with nonalcoholic fatty liver disease: baseline data from the nonalcoholic steatohepatitis clinical research network, Hepatology, 49, 1904, 10.1002/hep.22868 · DOI · Paper page
  167. 2019, Reduced patient‐reported outcome scores associate with level of fibrosis in patients with nonalcoholic steatohepatitis, Clin Gastroenterol Hepatol, 17, 2552, 10.1016/j.cgh.2019.02.024 · DOI · Paper page
  168. 2018, Improvement of hepatic fibrosis and patient‐reported outcomes in non‐alcoholic steatohepatitis treated with selonsertib, Liver Int, 38, 1849, 10.1111/liv.13706 · DOI · Paper page
  169. 2019, Referral pathways for patients with NAFLD based on non‐invasive fibrosis tests: diagnostic accuracy and cost analysis, Liver Int, 39, 2052, 10.1111/liv.14198 · DOI · Paper page
  170. 2020, Modelling the economic and clinical burden of non‐alcoholic steatohepatitis in East Asia: data from Hong Kong, Hepatol Res, 50, 1024, 10.1111/hepr.13535 · DOI
  171. 2021, Clinical and economic burden of nonalcoholic steatohepatitis in Saudi Arabia, United Arab Emirates and Kuwait, Hepatol Int, 15, 912, 10.1007/s12072-021-10182-x · DOI
  172. 2022, The global NAFLD policy review and preparedness index: are countries ready to address this silent public health challenge?, J Hepatol, 76, 771, 10.1016/j.jhep.2021.10.025 · DOI · Paper page
  173. 2020, The growing burden of disability related to nonalcoholic fatty liver disease: data from the global burden of disease 2007–2017, Hepatol Commun, 4, 1769, 10.1002/hep4.1599 · DOI · Paper page
  174. 2021, Defining comprehensive models of care for NAFLD, Nat Rev Gastroenterol Hepatol, 18, 717, 10.1038/s41575-021-00477-7 · DOI
  175. 2017, Visualizing the geography of genetic variants, Bioinformatics, 33, 594, 10.1093/bioinformatics/btw643 · DOI · Paper page

Cited by

See all 123

Metadata

Authors
Yip, T. C., Vilar‐Gomez, E., Petta, S., Yilmaz, Y., Wong, G. L., Adams, L. A., de Lédinghen, V., Sookoian, S., & Wong, V. W.
Venue
Hepatology
Published
2022-10-11
Volume
77
Issue
4
Pages
1404-1427
ISSN
0270-9139 (ISSN-L)
OpenAlex
W4294598083
Cited by
123
References
43
FWCI
15.62
Type
journal article
Language
en
Open access
closed
Licence

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.